Nymox Pharmaceutical Corporation
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Paul Averback
- Full Time Employees
- 16
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Bay & Deveaux Streets Nassau NW Bahamas H4M 2V2
- IPO Date
- Dec 22, 1997
- CIK
- 0001018735
- Website
- nymox.com
- Similar Companies
- Business
- Nymox Pharmaceutical Corporation, a biopharmaceutical company founded in 1995 and headquartered in Nassau, Bahamas with offices in Canada, the United States and Switzerland, develops therapeutics and diagnostics targeting unmet needs of the aging male population, particularly for benign prostatic hyperplasia (BPH) and low-grade localized prostate cancer; its lead product candidate Fexapotide Triflutate (also known as NYMOZARFEX), a protein injectable administered directly into the prostate, has completed Phase 3 clinical trials in over 70 U.S. centers involving more than 1,700 patients demonstrating long-term symptomatic improvements, reduced disease progression and lower rates of surgery or radiotherapy; the Company also markets NicAlert and TobacAlert diagnostic tests for measuring tobacco exposure in saliva or urine samples. Operations span North America and Europe, with marketing authorization applications submitted and accepted for review in the United Kingdom and Denmark for Fexapotide Triflutate in BPH treatment, and plans underway to file for approval in major economies including the United States and European countries. The Company holds extensive U.S. and international patents covering Fexapotide Triflutate for prostate disorders, statin use in Alzheimer's prevention, and its diagnostic products. In recent developments, Nymox resumed trading on the OTCQB Venture Market under ticker NYMXF in December 2024 following delisting from NASDAQ in July 2023 due to share price and market value compliance issues; completed a $2 million private placement in August 2023 and secured additional financings including $6.4 million in 2022; dismissed a Delaware lawsuit against AscellaHealth in March 2025 after filing a $250 million suit in 2023 alleging corporate espionage; achieved victories in Bahamas litigation against terminated ex-employees awarding costs and damages in 2024; relocated headquarters processes from the Bahamas to Switzerland initiated in 2018; and reported positive long-term clinical data for Fexapotide in prostate cancer in 2023 alongside manufacturing scale-up milestones.
NYMOX Provides Current Update
NYMOX Provides Recent Updates
Nymox Announces Dismissal of Delaware Action Against Ascella
NYMOX Announces Trading Resumed and New Listing on OTCQB Market
Nymox Announces Filing of Annual Report
Nymox Annual Report
Nymox Required to Resubmit Application to DKMA
Nymox Reports Victory in Bahamas Litigation Against Terminated Ex-Employees – Court Awards Costs and Damages
Nymox December 27 Message to Shareholders
Nymox Reports California Court Issues Preliminary Injunction Against Defendants Lanham, Riley, Cutler and Others
$250 Million Lawsuit Filed Against AscellaHealth by Nymox Accepted and Summons Issued in California Court
Nymox Pharmaceutical Corporation Sues AscellaHealth For $250 Million
NYMOX REPORTS: Bahamian Court Today Suspends Order of October 3, 2023 Rendering Riley-Lanham and Accomplices Planned Vote Unauthorized
NYMOX REPORTS NOTICE: California Court Issued A Temporary Restraining Order Enjoining Lanham, Riley, Cutler And Their Nevada Company After Court Hearing In Santa Ana, California, November 2, 2023
IMPORTANT MESSAGE TO NYMOX SHAREHOLDERS: NYMOX Cautions Against Unauthorized Improper Shareholder Meeting and Unauthorized Unregistered Solicitations
IMPORTANT NOTICE: NYMOX Cautions Shareholders Not to Take Calls or Participate in Unauthorized Improper Shareholder Meeting
Notice: Nymox Informs Its Shareholders Not to Take Calls or Participate in An Unauthorized and Improper Shareholder Meeting
Nymox Reports New NYMOZARFEX Marketing Application is Accepted For Review
The Committee to Restore Nymox Shareholder Value Sends Letter to Nymox Pharmaceutical Shareholders and Issues Proxy Materials for Upcoming Special Meeting
Nymox Announces Submission of New Marketing Authorization Application Submission for NYMOZARFEX (TM) for BPH